Cathepsin S inhibitors: WO2010070615.
This article evaluates a patent application of the company Medivir (SE/UK) describing the synthesis of dipeptide-derived α-ketoamides containing a propylene glycine moiety in P1 as selective inhibitors of cathepsin S for the potential treatment of various systemic human diseases such as several autoimmune diseases, MS, rheumatoid arthritis, endometriasis and chronic pain. The claims of the patent are discussed in light of recent results in the field of cathepsin S research.
Institute of Radiopharmacy, Research Centre Dresden-Rossendorf, Bautzner Landstraße 400, 01328 Dresden, Germany. r.loeser@hzdr.de
Reik
R
Löser
D002403:Cathepsins / Q000037:antagonists & inhibitors*; D003503:Cyclobutanes / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010330:Patents as Topic; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use
D003503:Cyclobutanes; D009842:Oligopeptides; D011480:Protease Inhibitors; D002403:Cathepsins; C028217:cathepsin S